Aug 25, 2026 08:00AM
Aug 11, 2026 08:00AM
Aug 11, 2026 08:00AM
Aug 3, 2026 08:03AM
Aug 3, 2026 08:00AM
Jul 30, 2026 08:00AM
May 6, 2026 07:00AM Anavex names Terrie Kellmeyer interim CEO after Missling departure
May 6, 2026 07:00AM
Mar 30, 2026 07:31AM
Mar 30, 2026 07:30AM
Feb 9, 2026 07:30AM
Jan 20, 2026 06:41AM
Jan 6, 2026 07:30AM
Jan 6, 2026 07:30AM Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program
Nov 14, 2025 07:31AM
Nov 14, 2025 07:30AM
Nov 14, 2025 07:30AM
Mar 31, 2025 06:43AM
Jul 29, 2024 07:15AM
Jul 28, 2024 05:00PM
Jul 28, 2024 05:00PM Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference
Jul 22, 2024 07:01AM
May 22, 2024 07:37AM
May 22, 2024 07:30AM
May 9, 2024 07:30AM
Apr 29, 2024 07:15AM
Apr 22, 2024 01:45AM
Apr 20, 2024 09:00PM Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Ventyx, Anavex, and Checkpoint and Encourages Investors to Contact the Firm
Apr 16, 2024 09:00PM
Apr 15, 2024 11:15AM
Apr 12, 2024 09:00PM
Apr 1, 2024 11:30AM
Mar 25, 2024 12:30PM
Mar 18, 2024 12:30PM
Mar 18, 2024 07:30AM Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
Mar 14, 2024 12:30PM
Feb 7, 2024 07:30AM
Jan 16, 2024 07:31AM
Jan 16, 2024 07:30AM
Jan 2, 2024 08:01AM
Jan 2, 2024 08:00AM
Nov 6, 2023 08:00AM Anavex Life Sciences Appoints Senior VP of Regulatory Affairs
Jun 28, 2023 07:30AM
Jun 28, 2023 07:30AM
Jun 12, 2023 07:30AM
Jun 6, 2023 07:30AM
May 9, 2023 07:30AM
Mar 9, 2023 07:00AM
Feb 2, 2023 07:00AM Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical Trial
Nov 28, 2022 07:00AM

330,674 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All